霍乱疫苗市场、机会、成长动力、产业趋势分析与预测，2024-2032

Cholera Vaccines Market, Opportunity, Growth Drivers, Industry Trend Analysis and Forecast, 2024-2032

出版日期: 2024年07月09日 | 出版商:

Global Market Insights Inc. | 英文 160 Pages | 商品交期: 2-3个工作天内

价格

简介目录

由于霍乱发病率上升以及对其公共卫生影响的认识不断提高，霍乱疫苗市场规模预计在 2024 年至 2032 年期间复合年增长率达到 8.4%。

据世界卫生组织称，2023 年，霍乱影响了超过 667,000 人，导致 4,000 人死亡。这种疾病仍然是许多发展中地区的一个紧迫问题，特别是在缺乏卫生设施和供水的地区。霍乱的频繁爆发往往因自然灾害和衝突而加剧，这凸显了迫切需要进行有效的疫苗接种活动来遏制疾病的传播。

创新已经为更有效、更持久的疫苗、加强保护和最大限度地减少接种频率铺平了道路。新疫苗配方的推出，加上口服疫苗等增强的给药方法，简化了资源有限环境中的给药，推动了市场的扩张。

整个产业分为产品、最终用户和地区。

从产品来看，Vaxchora 领域的霍乱疫苗市场规模预计到2032 年将产生可观的收入。疫苗。这种独特的口服製剂提供了一种方便有效的霍乱防护方法，满足了旅行前免疫的巨大需求。

就最终用户而言，由于个人和组织对预防性医疗解决方案的认识和需求不断增加，私营部门的霍乱疫苗市场价值预计在 2024 年至 2032 年期间将出现强劲的复合年增长率。私人医疗保健提供者和机构越来越多地提供霍乱疫苗接种服务，作为其预防保健和旅行健康计划的一部分。

由于霍乱疫情的高发生率以及与卫生和水质相关的持续公共卫生挑战，亚太地区霍乱疫苗产业规模将在 2024 年至 2032 年间大幅成长。快速的都市化、人口成长和环境因素导致霍乱的传播，进一步需要强而有力的疫苗接种工作。政府和非政府组织加强改善弱势社区的卫生基础设施和疾病预防倡议，提高了疫苗的使用率，促进了区域市场的成长。

产业生态系统分析
产业影响力
- 成长动力
  - 霍乱疫情的发生率不断增加。
  - 政府支持不断增加
  - 扩大研究经费和活动
  - 前往流行地区的旅行不断增加
- 产业陷阱与挑战
  - 无法获得足够的治疗
  - 冷链要求
成长潜力分析
监管环境
管道分析
波特的分析
PESTEL分析

第 4 章：竞争格局

介绍
公司矩阵分析
公司市占率分析
主要市场参与者的竞争分析
竞争定位矩阵
战略仪表板

第 5 章：市场估计与预测：按产品分类，2021 - 2032 年

主要趋势
杜科拉尔
瓦克斯乔拉
Euvichol/Euvichol-Plus
其他产品

第 6 章：市场估计与预测：按最终用户划分，2021 - 2032 年

主要趋势
民众
私人的

第 7 章：市场估计与预测：按地区，2021 - 2032

主要趋势
北美洲
- 我们
- 加拿大
欧洲
- 英国
- 法国
- 西班牙
- 荷兰
- 比利时
- 克罗埃西亚
- 欧洲其他地区
亚太地区
- 印度
- 孟加拉
- 巴基斯坦
- 菲律宾
- 亚太地区其他地区
拉丁美洲
- 哥伦比亚
- 秘鲁
- 智利
- 拉丁美洲其他地区
中东和非洲
- 叙利亚
- 乌干达
- 叶门
- 肯亚
- 辛巴威
- 中东和非洲其他地区

第 8 章：公司简介

Bavarian Nordic A/S
Bharat Biotech
Biological E
EuBiologics Co. Ltd.
Hilleman Laboratories
Incepta Pharmaceuticals Ltd.
Shantha Biotechnics (Sanofi)
Vabiotech
Valneva Sweden AB

简介目录

Product Code: 10163

Cholera vaccines market size is set to record an 8.4% CAGR during 2024-2032 driven by the rising incidence of cholera and heightened awareness of its public health implications.

According to the WHO, in 2023, cholera affected over 667,000 individuals, leading to 4,000 reported fatalities. The disease remains a pressing concern in numerous developing regions, especially where sanitation and water supply are lacking. Frequent cholera outbreaks, often intensified by natural disasters and conflicts, underscore the urgent need for effective vaccination campaigns to curb the spread of the disease.

Innovations have made way for more effective, longer-lasting vaccines, bolstering protection and minimizing the frequency of doses. The introduction of new vaccine formulations, coupled with enhanced delivery methods like oral vaccines that simplify administration in resource-limited settings fuels the market expansion.

The overall industry is segmented into product, end-user, and region.

Based on product, the cholera vaccines market size from the Vaxchora segment is expected to generate notable revenue by 2032. This is due to its role as the first and only FDA-approved oral cholera vaccine specifically designed for travelers to endemic regions. This unique oral formulation offers a convenient and effective means of protection against cholera, addressing a significant need for pre-travel immunization.

In terms of end-user, the cholera vaccines market value from the private segment is projected to observe a robust CAGR during 2024 - 2032 owing to the increasing awareness and demand for preventive healthcare solutions among individuals and organizations. Private healthcare providers and institutions are increasingly offering cholera vaccination services as part of their preventive care and travel health programs.

Asia Pacific cholera vaccines industry size will grow substantially between 2024 and 2032 attributed to the high incidence of cholera outbreaks and ongoing public health challenges related to sanitation and water quality. Rapid urbanization, population growth, and environmental factors contribute to the spread of cholera, further necessitating robust vaccination efforts. The increased government and NGO initiatives focused on improving health infrastructure and disease prevention in vulnerable communities are boosting vaccine uptake, adding to the regional market growth.

Chapter 1 Methodology and Scope

1.1 Market scope and definitions
1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
1.3 Base estimates and calculations
- 1.3.1 Base year calculations
- 1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources

Chapter 2 Executive Summary

2.1 Industry 360° synopsis

Chapter 3 Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Increasing incidence of cholera outbreaks.
  - 3.2.1.2 Growing governments support
  - 3.2.1.3 Expanding research funding and activities
  - 3.2.1.4 Growing travel to endemic regions
- 3.2.2 Industry pitfalls and challenges
  - 3.2.2.1 Lack of access to adequate treatment
  - 3.2.2.2 Cold chain requirements
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Pipeline analysis
3.6 Porter's analysis
3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

4.1 Introduction
4.2 Company matrix analysis
4.3 Company market share analysis
4.4 Competitive analysis of major market players
4.5 Competitive positioning matrix
4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Product, 2021 - 2032 ($ Mn)

5.1 Key trends
5.2 Dukoral
5.3 Vaxchora
5.4 Euvichol/Euvichol-Plus
5.5 Other products

Chapter 6 Market Estimates and Forecast, By End-User, 2021 - 2032 ($ Mn)

6.1 Key trends
6.2 Public
6.3 Private

Chapter 7 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

7.1 Key trends
7.2 North America
- 7.2.1 U.S.
- 7.2.2 Canada
7.3 Europe
- 7.3.1 UK
- 7.3.2 France
- 7.3.3 Spain
- 7.3.4 Netherlands
- 7.3.5 Belgium
- 7.3.6 Croatia
- 7.3.7 Rest of Europe
7.4 Asia Pacific
- 7.4.1 India
- 7.4.2 Bangladesh
- 7.4.3 Pakistan
- 7.4.4 Philippines
- 7.4.5 Rest of Asia Pacific
7.5 Latin America
- 7.5.1 Columbia
- 7.5.2 Peru
- 7.5.3 Chile
- 7.5.4 Rest of Latin America
7.6 Middle East and Africa
- 7.6.1 Syria
- 7.6.2 Uganda
- 7.6.3 Yemen
- 7.6.4 Kenya
- 7.6.5 Zimbabwe
- 7.6.6 Rest of Middle East and Africa